Cargando…
Peripheral neuropathy in persons with tuberculosis
Peripheral neuropathy (PN) is a serious condition affecting the nerves that is commonly seen in patients with tuberculosis (TB). Causes of PN in patients with TB are multiple, and can include TB itself, other co-morbid conditions, such as Human Immune-deficiency virus (HIV) disease, malnutrition, or...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852705/ https://www.ncbi.nlm.nih.gov/pubmed/31768422 http://dx.doi.org/10.1016/j.jctube.2015.11.002 |
_version_ | 1783469895130808320 |
---|---|
author | Mafukidze, Arnold T Calnan, Marianne Furin, Jennifer |
author_facet | Mafukidze, Arnold T Calnan, Marianne Furin, Jennifer |
author_sort | Mafukidze, Arnold T |
collection | PubMed |
description | Peripheral neuropathy (PN) is a serious condition affecting the nerves that is commonly seen in patients with tuberculosis (TB). Causes of PN in patients with TB are multiple, and can include TB itself, other co-morbid conditions, such as Human Immune-deficiency virus (HIV) disease, malnutrition, or diabetes mellitus (DM), and several anti-tuberculous medications. The condition can manifest with a variety of symptoms, and a diagnosis can usually be made on a clinical basis. Treatment and prognosis of PN vary depending on the underlying cause, but often the condition can lead to permanent disability in individuals with TB. For this reason, primary prevention is key as is early identification and management of symptoms. Treatment can include withdrawal of possible offending agents, vitamin supplementation, physical therapy, analgesics, and targeted agents, including tricyclic antidepressants, selective serotonin reuptake inhibitors, and gabapentin. Additional research is needed to better describe the morbidity and disability associated with PN in persons with TB and to improve management strategies for persons at risk for and affected by this condition. Case review: RM is a 47 year-old man who is in his third month of treatment for drug-resistant TB (DR-TB). His treatment regimen consists of kanamycin (1 gm intramuscular daily), levofloxacin (1000 mg by mouth daily), cycloserine (750 mg by mouth daily), ethionamide (750 mg by mouth daily), pyrazinamide (1500 mg by mouth daily), and Para-Amino Salicylate (12 gm by mouth daily). He is HIV-infected with a CD4 count of 470 cell/µl and on a stable antiretroviral therapy regimen of tenofovir, lamivudine, and efavirenz, which he started 8 weeks ago. He works in a platinum mine, denies smoking, reports drinking beer “on the weekend” and denies other drugs. He presents for his 3 month clinical visit for his DR-TB follow-up and states he is doing well, but he does report some “burning” in the bottom of his feet. |
format | Online Article Text |
id | pubmed-6852705 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-68527052019-11-25 Peripheral neuropathy in persons with tuberculosis Mafukidze, Arnold T Calnan, Marianne Furin, Jennifer J Clin Tuberc Other Mycobact Dis Article Peripheral neuropathy (PN) is a serious condition affecting the nerves that is commonly seen in patients with tuberculosis (TB). Causes of PN in patients with TB are multiple, and can include TB itself, other co-morbid conditions, such as Human Immune-deficiency virus (HIV) disease, malnutrition, or diabetes mellitus (DM), and several anti-tuberculous medications. The condition can manifest with a variety of symptoms, and a diagnosis can usually be made on a clinical basis. Treatment and prognosis of PN vary depending on the underlying cause, but often the condition can lead to permanent disability in individuals with TB. For this reason, primary prevention is key as is early identification and management of symptoms. Treatment can include withdrawal of possible offending agents, vitamin supplementation, physical therapy, analgesics, and targeted agents, including tricyclic antidepressants, selective serotonin reuptake inhibitors, and gabapentin. Additional research is needed to better describe the morbidity and disability associated with PN in persons with TB and to improve management strategies for persons at risk for and affected by this condition. Case review: RM is a 47 year-old man who is in his third month of treatment for drug-resistant TB (DR-TB). His treatment regimen consists of kanamycin (1 gm intramuscular daily), levofloxacin (1000 mg by mouth daily), cycloserine (750 mg by mouth daily), ethionamide (750 mg by mouth daily), pyrazinamide (1500 mg by mouth daily), and Para-Amino Salicylate (12 gm by mouth daily). He is HIV-infected with a CD4 count of 470 cell/µl and on a stable antiretroviral therapy regimen of tenofovir, lamivudine, and efavirenz, which he started 8 weeks ago. He works in a platinum mine, denies smoking, reports drinking beer “on the weekend” and denies other drugs. He presents for his 3 month clinical visit for his DR-TB follow-up and states he is doing well, but he does report some “burning” in the bottom of his feet. Elsevier 2015-12-03 /pmc/articles/PMC6852705/ /pubmed/31768422 http://dx.doi.org/10.1016/j.jctube.2015.11.002 Text en © 2015 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Mafukidze, Arnold T Calnan, Marianne Furin, Jennifer Peripheral neuropathy in persons with tuberculosis |
title | Peripheral neuropathy in persons with tuberculosis |
title_full | Peripheral neuropathy in persons with tuberculosis |
title_fullStr | Peripheral neuropathy in persons with tuberculosis |
title_full_unstemmed | Peripheral neuropathy in persons with tuberculosis |
title_short | Peripheral neuropathy in persons with tuberculosis |
title_sort | peripheral neuropathy in persons with tuberculosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852705/ https://www.ncbi.nlm.nih.gov/pubmed/31768422 http://dx.doi.org/10.1016/j.jctube.2015.11.002 |
work_keys_str_mv | AT mafukidzearnoldt peripheralneuropathyinpersonswithtuberculosis AT calnanmarianne peripheralneuropathyinpersonswithtuberculosis AT furinjennifer peripheralneuropathyinpersonswithtuberculosis |